» Articles » PMID: 34573139

CSF Secretion Is Not Altered by NKCC1 Nor TRPV4 Antagonism in Healthy Rats

Overview
Journal Brain Sci
Publisher MDPI
Date 2021 Sep 28
PMID 34573139
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Cerebrospinal fluid (CSF) secretion can be targeted to reduce elevated intracranial pressure (ICP). Sodium-potassium-chloride cotransporter 1 (NKCC1) antagonism is used clinically. However, supporting evidence is limited. The transient receptor potential vanilloid-4 (TRPV4) channel may also regulate CSF secretion and ICP elevation. We investigated whether antagonism of these proteins reduces CSF secretion.

Methods: We quantified CSF secretion rates in male Wistar rats. The cerebral aqueduct was blocked with viscous mineral oil, and a lateral ventricle was cannulated. Secretion rate was measured at baseline and after antagonist administration. Acetazolamide was administered as a positive control to confirm changes in CSF secretion rates.

Results: Neither NKCC1, nor TRPV4 antagonism altered CSF secretion rate from baseline, = 3, t(2) = 1.14, = 0.37, and = 4, t(3) = 0.58, = 0.6, respectively. Acetazolamide reduced CSF secretion by ~50% across all groups, = 7, t(6) = 4.294, = 0.005.

Conclusions: Acute antagonism of NKCC1 and TRPV4 proteins at the choroid plexus does not reduce CSF secretion in healthy rats. Further investigation of protein changes and antagonism should be explored in neurological disease where increased CSF secretion and ICP are observed before discounting the therapeutic potential of protein antagonism at these sites.

Citing Articles

Mechanisms of cerebrospinal fluid and brain interstitial fluid production.

Xiang J, Hua Y, Xi G, Keep R Neurobiol Dis. 2023; 183:106159.

PMID: 37209923 PMC: 11071066. DOI: 10.1016/j.nbd.2023.106159.


Consideration of Kinase Inhibitors for the Treatment of Hydrocephalus.

Blazer-Yost B Int J Mol Sci. 2023; 24(7).

PMID: 37047646 PMC: 10094860. DOI: 10.3390/ijms24076673.


Are standing osmotic gradients the main driver of cerebrospinal fluid production? A computational analysis.

Razzaghi Khamesi P, Charitatos V, Heerfordt E, MacAulay N, Kurtcuoglu V Fluids Barriers CNS. 2023; 20(1):18.

PMID: 36915140 PMC: 10012606. DOI: 10.1186/s12987-023-00419-2.


TRPV4: Cell type-specific activation, regulation and function in the vertebrate eye.

Lapajne L, Rudzitis C, Cullimore B, Ryskamp D, Lakk M, Redmon S Curr Top Membr. 2022; 89:189-219.

PMID: 36210149 PMC: 9879314. DOI: 10.1016/bs.ctm.2022.07.005.


Lysophosphatidic acid as a CSF lipid in posthemorrhagic hydrocephalus that drives CSF accumulation via TRPV4-induced hyperactivation of NKCC1.

Toft-Bertelsen T, Barbuskaite D, Heerfordt E, Lolansen S, Andreassen S, Rostgaard N Fluids Barriers CNS. 2022; 19(1):69.

PMID: 36068581 PMC: 9450297. DOI: 10.1186/s12987-022-00361-9.


References
1.
Murtha L, McLeod D, McCann S, Pepperall D, Chung S, Levi C . Short-duration hypothermia after ischemic stroke prevents delayed intracranial pressure rise. Int J Stroke. 2013; 9(5):553-9. DOI: 10.1111/ijs.12181. View

2.
Ropper A, Shafran B . Brain edema after stroke. Clinical syndrome and intracranial pressure. Arch Neurol. 1984; 41(1):26-9. DOI: 10.1001/archneur.1984.04050130032017. View

3.
Uldall M, Botfield H, Jansen-Olesen I, Sinclair A, Jensen R . Acetazolamide lowers intracranial pressure and modulates the cerebrospinal fluid secretion pathway in healthy rats. Neurosci Lett. 2017; 645:33-39. DOI: 10.1016/j.neulet.2017.02.032. View

4.
Sorby-Adams A, Leonard A, Hoving J, Yassi N, Vink R, Wells A . NK1-r Antagonist Treatment Comparable to Decompressive Craniectomy in Reducing Intracranial Pressure Following Stroke. Front Neurosci. 2019; 13:681. PMC: 6624444. DOI: 10.3389/fnins.2019.00681. View

5.
Bairamian D, Johanson C, Parmelee J, Epstein M . Potassium cotransport with sodium and chloride in the choroid plexus. J Neurochem. 1991; 56(5):1623-9. DOI: 10.1111/j.1471-4159.1991.tb02060.x. View